Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
The company has raised US$4.5 million in funding for its AI operating system
Total transaction value of the divestment is Rs. 3,660 million
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Subscribe To Our Newsletter & Stay Updated
